Skip to main content
OpenTrials
Completed

NCT Number: NCT03392467

PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants

This study is to evaluate the efficacy and safety of PNEUMOSTEM® for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia (Severe BPD) in Premature Infants. Half of subjects will receive PNEUMOSTEM, while the other half will receive a placebo.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 13 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Asan medical Center, Seoul, South Korea

Loading trial locations.

About this study

Bronchopulmonary dysplasia (BPD) is a chronic lung disease in which premature infants and it results in significant morbidity and mortality. PNEUMOSTEM is intended to prevent and treat BPD by modulating inflammation and repairing damaged lung tissue in premature infants through paracrine effects.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

at screening and randomization

  • 23 weeks to < 25 weeks of gestational age
  • 500g to 1,250g body weight at birth
  • premature infant within postnatal 13 days of age
  • use ventilator with ventilation rate >12 breaths/min or oxygen supply > 25%, or use high frequency ventilator (HFV)

at IP administration

  • premature infant within postnatal 5 to 14 days of age
  • No improvement in ventilator setting 24 hours prior to administration of IP

Exclusion criteria

  • subject with cyanotic congenital heart disease or non-cyanotic congenital heart disease that can cause heart failure
  • subject with pulmonary hypoplasia, congenital diaphragmatic hernia, or serious lung malformation such as congenital cystic lung disease
  • subject with chromosome disorder with serious malformation (i.e. Edward syndrome, patau syndrome, Down syndrome, etc.), severe congenital malformation (i.e. hydrocephalus, encephalocele, etc.), or severe congenital infection (i.e., herpes, toxoplasmosis, rubella, syphilis, AIDS, etc.)
  • subject with serious sepsis as active infection or shock due to sepsis
  • subject with grade 3 or 4 of bilateral intraventricular hemorrhage
  • at screening, subject with active pulmonary hemorrhage or active air leak syndrome
  • subject who underwent/will undergo surgery within 72 hours before/after investigational product (IP) administration
  • subject who is expected to be treated with surfactant within 24 hours prior to IP administration
  • subject who is expected to be allergic to gentamicin (Birth mother's allergy for gentamicin will be confirmed).
  • subject who have previously participated in other clinical trials
  • subject who is considered ineligible by investigator due to other medical reasons

Treatment and study plan

PNEUMOSTEM

Biological

human umbilical cord blood-derived mesenchymal stem cells

Placebo

Other

normal saline

Primary outcomes

  1. Percentage of subjects who have severe BPD or are dead

    Time frame: 36 weeks postmenstrual age (PMA)

    Percentage of subjects who have severe BPD or are dead

Secondary outcomes

  1. Percentage of subjects who have moderate/severe BPD or are dead

    Time frame: 36 weeks PMA

    Percentage of subjects who have moderate/severe BPD or are dead

  2. Percentage of subjects by severity of BPD

    Time frame: prenatal 28 days/36 weeks PMA

    Percentage of subjects by severity of BPD

  3. Percentage of subjects in death due to lung disease

    Time frame: prenatal 28 days/36 weeks PMA and study end timepoint

    Percentage of subjects in death due to lung disease

  4. intubation duration

    Time frame: up to 24 weeks

    intubation duration

  5. ventilation duration

    Time frame: up to 24 weeks

    ventilation duration

  6. continuous positive airway pressure (CPAP) treatment duration

    Time frame: up to 24 weeks

    continuous positive airway pressure (CPAP) treatment duration

  7. treatment duration with supplemental oxygen

    Time frame: up to 24 weeks

    treatment duration with supplemental oxygen

  8. % of subjects treated with steroid for weaning ventilator

    Time frame: up to 24 weeks

    % of subjects treated with steroid for weaning ventilator

  9. Retinopathy of prematurity (ROP) with stage III or higher

    Time frame: up to 24 weeks

    number of subjects with ROP with stage III or higher

  10. number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy

    Time frame: up to 24 weeks

    number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy

  11. z-score

    Time frame: up to 24 weeks (visit 10)

    percentile for body weight, height, and head circumference

  12. days in hospitalization

    Time frame: up to 24 weeks

    days in hospitalization

  13. changes in tracheal suction fluid examination

    Time frame: from screening to 7 days after IP administration (visit 5)

    changes in tracheal suction fluid examination

Sponsors and collaborators

Lead sponsor

Medipost Co Ltd.

Industry

Registry information

Official study title

A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of PNEUMOSTEM for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia in Premature Infants

Important dates

Study start
2018
Primary completion
2024
Study completion
2024
First posted
Jan 8, 2018
Registry last updated
Jan 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.